The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race ...

Merck has entered a $2 billion licensing deal with China's Hansoh Pharma for an oral weight-loss drug, positioning itself ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market, this time to Shanghai-based Hansoh ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

In other news of note, Merck (MRK) joins the weight-loss drug race. Merck and China’s Hansoh Pharma (OTCPK:HNSPF) announced a ...

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...

( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...

US pharma giant Merck & Co and Chinese biopharma Hansoh Pharma have entered into an exclusive global license agreement for HS ...